Treatment of Peyronie's disease with PDE5 inhibitors: An antifibrotic strategy

Nature Reviews Urology

Volumn 7, Issue 4, 2010, Pages 215-221

  Gonzalez Cadavid, Nestor F ^a   Rajfer, Jacob ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; COLLAGEN; COLLAGENASE; CYCLIC AMP; CYCLIC GMP; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA1; VARDENAFIL; VERAPAMIL;

AGE; CORPUS CAVERNOSUM; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DUPUYTREN CONTRACTURE; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PENILE FIBROSIS; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUNICA ALBUGINEA;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FIBROSIS; HUMANS; MALE; PENILE INDURATION; PENIS; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77951022374     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.24     Document Type: Review

References (99)

1. Gonzalez-Cadavid, N. F. & Rajfer, J. in Current Clinical Urology: Peyronie's Disease, A Guide to Clinical Management (ed. Levine, L. A. ) 19-39 (Humana Press, Totowa, 2007).
2. Smith, J. F., Walsh, T. J. & Lue, T. F. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int. J. Impot. Res. 20, 445-459 (2008).
3. Müller, A. & Mulhall, J. P. Peyronie's disease intervention trials: methodological challenges and issues. J. Sex. Med. 6, 848-861 (2009).
4. Smith, C. J., McMahon, C. & Shabsigh, R. Peyronie's disease: the epidemiology, aetiology and clinical evaluation of deformity. BJU Int. 95, 729-732 (2005). (Pubitemid 40547196)
5. Mulhall, J. P. et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J. Urol. 171, 2350-2353 (2004).
6. Taylor, F. L. & Levine, L. A. Peyronie's disease. Urol. Clin. North Am. 34, 517-534 (2007).
7. Carrieri, M. P., Serraino, D., Palmiotto, F., Nucci, G. & Sasso, F. A case-control study on risk factors for Peyronie's disease. J. Clin. Epidemiol. 51, 511-515 (1998). (Pubitemid 28310239)
8. Deveci, S. et al. Defining the clinical characteristics of Peyronie's disease in young men. J. Sex. Med. 4, 485-490 (2007). (Pubitemid 46394722)
9. Bjekic, M. D., vlajinac, H. D., Sipetic, S. B. & Marinkovic, J. M. Risk factors for Peyronie's disease: a case-control study. BJU Int. 97, 570-574 (2006).
10. Gonzalez-Cadavid, N. F. & Rajfer, J. Experimental models of Peyronie's disease. Implications for new therapies. J. Sex. Med. 6, 303-313 (2009).
11. valente, E. G. et al. l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229-244 (2003).
12. Devine, C. J. Jr, Somers, K. D., Jordan, S. G. & Schlossberg, S. M. Proposal: trauma as the cause of the Peyronie's lesion. J. Urol. 157, 285-290 (1997).
13. Somers, K. D. & Dawson, D. M. Fibrin deposition in Peyronie's disease plaque. J. Urol. 157, 311-315 (1997).
14. Davila, H. H., Magee, T. R., Zuniga, F. I., Rajfer, J. & Gonzalez-Cadavid, N. F. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 65, 645-648 (2005). (Pubitemid 40522991)
15. Davila, H. H., Ferrini, M. G., Rajfer, J. & Gonzalez-Cadavid, N. F. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int. 91, 830-838 (2003). (Pubitemid 36724070)
16. Ehrlich, H. P. Scar contracture: cellular and connective tissue aspects in Peyronie's disease. J. Urol. 157, 316-319 (1997).
17. Davila, H. H., Magee, T. R., vernet, D., Rajfer, J. & Gonzalez-Cadavid, N. F. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol. Reprod. 71, 1568-1577 (2004). (Pubitemid 39403252)
18. Usta, M. F. et al. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J. Urol. 171, 775-779 (2004).
19. Perimenis, P., Athanasopoulos, A., Gyftopoulos, K., Katsenis, G. & Barbalias, G. Peyronie's disease: epidemiology and clinical presentation of 134 cases. Int. Urol. Nephrol. 32, 691-694 (2001). (Pubitemid 34272337)
20. El-Sakka, A. I., Selph, C. A., Yen, T. S., Dahiya, R. & Lue, T. F. The effect of surgical trauma on rat tunica albuginea. J. Urol. 159, 1700-1707 (1998). (Pubitemid 29117387)
21. Schiavino, D. et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 50, 764-768 (1997). (Pubitemid 27495000)
22. Noss, M. B., Day, N. S., Christ, G. J. & Melman, A. The genetics and immunology of Peyronie's disease. Int. J. Impot. Res. 12 (Suppl. 4), S127-S132 (2000).
23. Hauck, E. W., Hauptmann, A., Weidner, W., Bein, G. & Hackstein, H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease. J. Urol. 170, 1443-1446 (2003). (Pubitemid 37108179)
24. Anafarta, K., Bedük, Y., Uluoglu, O., Aydos, K. & Baltaci, S. The significance of histopathological changes of the normal tunica albuginea in Peyronie's disease. Int. Urol. Nephrol. 26, 71-77 (1994). (Pubitemid 24151936)
25. Ferrini, M. G. et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 6, 283-294 (2002). (Pubitemid 34852372)
26. Hinz, B. et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816 (2007).
27. Eyden, B. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J. Cell. Mol. Med. 12, 2022-2037 (2008).
28. Somers, K. D. et al. Cell culture of Peyronie's disease plaque and normal penile tissue. J. Urol. 127, 585-588 (1982).
29. Mulhall, J. P., Anderson, M. S., Lubrano, T. & Shankey, T. v. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int. J. Impot. Res. 14, 397-405 (2002). (Pubitemid 35285291)
30. vernet, D. et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 7, 262-276 (2002). (Pubitemid 35365671)
31. vernet, D. et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol. Reprod. 73, 1199-1210 (2005). (Pubitemid 41698610)
32. vernet, D. et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J. Sex. Med. 3, 84-94 (2006).
33. vande Berg, J. S. et al. Mechanisms of calcification in Peyronie's disease. J. Urol. 127, 52-54 (1982).
34. Kadioglu, A. et al. A retrospective review of 307 men with Peyronie's disease. J. Urol. 168, 1075-1079 (2002).
35. Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
36. El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R. & Lue, T. F. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J. Urol. 158, 1391-1394 (1997). (Pubitemid 27391204)
37. El-Sakka, A. I. et al. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J. Urol. 158, 2284-2290 (1997). (Pubitemid 27481391)
38. El-Sakka, A. I. et al. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br. J. Urol. 81, 445-452 (1998).
39. Bivalacqua, T. J. et al. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J. Urol. 163, 1992-1998 (2000).
40. Ferrini, M. G., Kovanecz, I., Nolazco, G., Rajfer, J. & Gonzalez-Cadavid, N. F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 97, 625-633 (2006).
41. Cantini, L. P. et al. Profibrotic role of myostatin in Peyronie's disease. J. Sex. Med. 5, 1607-1622 (2008).
42. Piao, S. et al. Repeated intratunical injection of adenovirus expressing transforming growth factor-β1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease. Int. J. Androl. 31, 346-353 (2008). (Pubitemid 351652031)
43. Rajfer, J., Gore, J. L., Kaufman, J. & Gonzalez-Cadavid, N. Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J. Sex. Med. 3, 173-176 (2006).
44. Lucattelli, M. et al. A new mouse model of Peyronie's disease: an increased expression of hypoxia-induciblefactor-1 target genes during the development of penile changes. Int. J. Biochem. Cell Biol. 40, 2638-2648 (2008).
45. Nolazco, G. et al. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int. 101, 1156-1164 (2008). (Pubitemid 351502662)
46. Mulhall, J. P. Expanding the paradigm for plaque development in Peyronie's disease. Int. J. Impot. Res. 15 (Suppl. 5), S93-S102 (2003). (Pubitemid 37314337)
47. Mulhall, J. P. et al. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int. J. Impot. Res. 16, 99-104 (2004).
48. Gonzalez-Cadavid, N. F. & Rajfer, J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat. Clin. Pract. Urol. 2, 291-297 (2005). (Pubitemid 40903186)
49. Gonzalez-Cadavid, N. F. Mechanisms of penile fibrosis. J. Sex. Med. 6 (Suppl. 3), 353-362 (2009).
50. Nehra, A. & Nylhall, J. Peyronie's disease. In Standard Practice in Sexual Medicine 1st edn (eds Porst, H. & Buvat, J.) 158-173 (Blackwell, Malden, 2006).
51. Mulhall, J. P. Expanding the paradigm for plaque development in Peyronie's disease. Int. J. Impot. Res. 15 (Suppl. 5), S93-S102 (2003). (Pubitemid 37314337)
52. Del Carlo, M., Cole, A. A. & Levine, L. A. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1β and transforming growth factor-β in Peyronie's plaque fibroblasts. J. Urol. 179, 2447-2455 (2008).
53. Magee, T. R. et al. Gene expression profiles in the Peyronie's disease plaque. Urology 59, 451-457 (2002). (Pubitemid 34189763)
54. Qian, A., Meals, R. A., Rajfer, J. & Gonzalez-Cadavid, N. F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64, 399-404 (2004). (Pubitemid 39092491)
55. Hellstrom, W. Medical management of Peyronie's disease. J. Androl. 30, 397-404 (2009).
56. Sivakumar, P. & Das, A. M. Fibrosis, chronic inflammation and new pathways for drug discovery. Inflamm. Res. 57, 410-418 (2008).
57. Gonzalez-Cadavid, N. F. & Rajfer, J. The pleiotropic effects of inducible nitric oxide synthase on the physiology and pathology of penile erection. Curr. Pharm. Des. 11, 4041-4046 (2005). (Pubitemid 41672475)
58. Ferrini, M. G., Davila, H., valente, E. G., Gonzalez-Cadavid, N. F. & Rajfer, J. Aging-related induction of inducible nitric oxide synthase (iNOS) is vasculo-protective in the arterial media. Cardiovasc. Res. 61, 796-805 (2004). (Pubitemid 38249479)
59. Ferrini, M. G. et al. Long-term continuous treatment with vardenafil prevents fibrosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernosal nerve transection. Urology 68, 429-435 (2006).
60. Ferrini, M. G. et al. Long-term continuous treatment with sildenafil ameliorates agingrelated erectile dysfunction and the underlying corporal fibrosis in the rat. Biol. Reprod. 76, 915-923 (2007).
61. Kovanecz, I. et al. Long term sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CvOD) induced by cavernosal nerve resection in rats. Int. J. Impot. Res. 100, 867-874 (2007). (Pubitemid 351374330)
62. Kovanecz, I. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction (CvOD) that occurs following cavernosal nerve resection in the rat. BJU Int. 101, 203-210 (2008). (Pubitemid 350294044)
63. Ferrini, M. G. et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CvOD) induced by experimental cavernosal nerve damage in the rat. J. Sex. Med. 6, 415-428 (2009).
64. Ferrini, M. G. et al. The genetic inactivation of inducible nitric oxide synthase intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J. Sex. Med. (in press).
65. Hochberg, D. et al. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab. Invest. 80, 1721-1728 (2000).
66. Trachtman, H., Futterweit, S., Pine, E., Mann, J. & valderrama, E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr. Nephrol. 17, 20-29 (2002). (Pubitemid 41490200)
67. Chen, Y. et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem. Biophys. Res. Commun. 326, 45-51 (2005). (Pubitemid 39573198)
68. Aram, G., Potter, J. J., Liu, X., Torbenson, M. S. & Mezey, E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology 47, 2051-2058 (2008). (Pubitemid 351945571)
69. Bayir, H. et al. Enhanced oxidative stress in iNOS deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS. J. Cereb. Blood Flow Metab. 25, 673-684 (2005). (Pubitemid 40705603)
70. Park, K. M. et al. Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J. Biol. Chem. 278, 27256-27266 (2003).
71. Jones, S. P. & Bolli, R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16-23 (2006). (Pubitemid 43012113)
72. Hesse, M., Cheever, A. W., Jankovic, D. & Wynn, T. A. NOS-2 mediates the protective antiinflammatory and antifibrotic effects of the Th1- inducing adjuvant, IL-12, in a Th2 model 0f granulomatous disease. Am. J. Pathol. 157, 945-955 (2000). (Pubitemid 32109386)
73. Zhang, P. et al. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ. Res. 100, 1089-1098 (2007). (Pubitemid 46598934)
74. Lu, L., Chen, S. S., Hassid, A. & Sun, Y. Cardiac fibrogenesis following infarction in mice with deletion of inducible nitric oxide synthase. Am. J. Med. Sci. 335, 431-438 (2008).
75. Kadkhodaee, M. et al. Proteinuria is reduced by inhibition of inducible nitric oxide synthase in rat renal ischemia-reperfusion injury. Transplant. Proc. 41, 2907-2909 (2009). (Pubitemid 40052306)
76. Kuhlencordt, P. J., Chen, J., Han, F., Astern, J. & Huang, P. L. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103, 3099-3104 (2001). (Pubitemid 32587858)
77. Toblli, J. E. et al. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transplant. 24, 2384-2391 (2009).
78. Mookerjee, I. et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 23, 1219-1229 (2009).
79. vyas-Read, S., Shaul, P. W., Yuhanna, I. S. & Willis, B. C. Nitric oxide attenuates epithelialmesenchymal transition in alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L212-L221 (2007). (Pubitemid 47080729)
80. Brosius, F. C. 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 9, 245-254 (2008).
81. Kalk, P. et al. Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system. Can. J. Physiol. Pharmacol. 86, 541-545 (2008).
82. Peters, H. et al. NO mediates antifibrotic actions of l-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int. 64, 509-518 (2003). (Pubitemid 36871922)
83. Dunkern, T. R., Feurstein, D., Rossi, G. A., Sabatini, F. & Hatzelmann, A. Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 572, 12-22 (2007). (Pubitemid 47374681)
84. Masuyama, H. et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressureoverloaded rat heart. Hypertens. Res. 32, 597-603 (2009).
85. Sawada, N. et al. Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and antifibrotic signals in blood vessels. Mol. Cell. Biol. 29, 6018-6032 (2009).
86. Knorr, A. et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58, 71-80 (2008). (Pubitemid 351346426)
87. Wang-Rosenke, Y., Neumayer, H. H. & Peters, H. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr. Med. Chem. 15, 1396-1406 (2008). (Pubitemid 351997790)
88. Iacono, F. et al. Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol. Int. 80, 249-252 (2008). (Pubitemid 351693072)
89. vignozzi, L. et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int. J. Impot. Res. 20, 60-67 (2008).
90. Magheli, A. & Burnett, A. L. Erectile dysfunction following prostatectomy: prevention and treatment. Nat. Rev. Urol. 6, 415-427 (2009).
91. Hemnes, A. R., Zaiman, A. & Champion, H. C. PDE 5A inhibition attenuates bleomycininduced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L24-L33 (2008). (Pubitemid 351380315)
92. Wang, Y. et al. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am. J. Physiol. Renal Physiol. 290, F167-F176 (2006).
93. Nagayama, T. et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol. 53, 207-215 (2009).
94. Radovits, T. et al. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br. J. Pharmacol. 156, 909-919 (2009).
95. Hohenstein, B., Daniel, C., Wittmann, S. & Hugo, C. PDE-5 inhibition impedes TSP-1 expression, TGF-β activation and matrix accumulation in experimental glomerulonephritis. Nephrol. Dial. Transplant. 23, 3427-3436 (2008).
96. Steiropoulos, P., Trakada, G. & Bouros, D. Current pharmacological treatment of pulmonary arterial hypertension. Curr. Clin. Pharmacol. 3, 11-19 (2008). (Pubitemid 351210961)
97. Levine, L. A. & Latchamsetty, K. C. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int. J. Impot. Res. 14, 478-482 (2002). (Pubitemid 36068424)
98. Porst, H. et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J. Sex. Med. 5, 2160-2169 (2008).
99. Bella, A. J., Deyoung, L. X., Al-Numi, M. & Brock, G. B. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur. Urol. 52, 990-1005 (2007).